These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20477141)

  • 1. Management of systemic lupus erythematosus in Chinese patients.
    Mok CC
    Expert Rev Clin Immunol; 2007 Nov; 3(6):925-35. PubMed ID: 20477141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese.
    Mok CC
    Lupus; 2011 Jun; 20(7):767-71. PubMed ID: 21148605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drug therapies for systemic lupus erythematosus.
    Mok CC
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):597-608. PubMed ID: 17064220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K; Yu Y; Tang Z; Liu Z; Li L
    Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong.
    Szeto CC; Mok HY; Chow KM; Lee TC; Leung JY; Li EK; Tsui TK; Yu S; Tam LS
    J Rheumatol; 2008 Jun; 35(6):1031-7. PubMed ID: 18398942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong.
    Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
    Rheumatology (Oxford); 2009 May; 48(5):564-8. PubMed ID: 19269959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors.
    Lee PP; Lee TL; Ho MH; Wong WH; Lau YL
    Pediatr Infect Dis J; 2006 Aug; 25(8):728-32. PubMed ID: 16874173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus.
    Borchers AT; Keen CL; Shoenfeld Y; Gershwin ME
    Autoimmun Rev; 2004 Aug; 3(6):423-53. PubMed ID: 15351310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premature atherosclerosis in systemic lupus erythematosus.
    Nikpour M; Urowitz MB; Gladman DD
    Rheum Dis Clin North Am; 2005 May; 31(2):329-54, vii-viii. PubMed ID: 15922149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lupus in the developing world--is it any different?
    Tikly M; Navarra SV
    Best Pract Res Clin Rheumatol; 2008 Aug; 22(4):643-55. PubMed ID: 18783742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
    Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
    J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study.
    Lalani S; Pope J; de Leon F; Peschken C;
    J Rheumatol; 2010 Jan; 37(1):38-44. PubMed ID: 20008925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis.
    Ståhl-Hallengren C; Jönsen A; Nived O; Sturfelt G
    J Rheumatol; 2000 Mar; 27(3):685-91. PubMed ID: 10743809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
    Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
    J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
    Fernández M; Calvo-Alén J; Alarcón GS; Roseman JM; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Sanchez ML; Reveille JD
    Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
    Mak A; Cheung BM; Mok CC; Leung R; Lau CS
    Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive strategies in systemic lupus erythematosus.
    Doria A; Arienti S; Rampudda M; Canova M; Tonon M; Sarzi-Puttini P
    Autoimmun Rev; 2008 Jan; 7(3):192-7. PubMed ID: 18190877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.